BIO4 is a viable bone matrix containing endogenous bone forming cells and is intended to facilitate bone repair and regeneration. It aims at providing a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities.
“With the introduction of BIO4, Stryker now plays in the growing $199M Cellular Allograft Market,” said Spencer Stiles, president of Stryker Spine.
More articles on devices:
Synergy Disc Replacement names GM Medical Pacific exclusive distributor — 5 things to know
7 key trends in the China orthopedic device market
Innovating beyond implants — DePuy Synthes launches data-collection software & patient video
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
